This is a promotional poster produced and fully funded by Bayer plc for UK healthcare professionals only. Prescribing information and adverse event reporting information for EYLEA® (aflibercept) 2 mg and EYLEA 8 mg can be accessed via the link or QR code located at the bottom of this document.

EYLEA® 8mg
(aflibercept 114.3mg/mL, solution for injection)

Global EYLEA® (aflibercept) 8 mg real-world evidence

12-month real-world outcomes in patients from Switzerland with nAMD

Swiss Retina Research Network (SRRN)

nAMD

These data are from real patients. Individual results may vary.

Study design:
Retrospective study evaluated outcomes in 91 treatment-naïve eyes.[1]

Treatment-naïve eyes received EYLEA 8 mg loading injections followed by a T&E (68.1% of patients) or O&P (31.9% of patients) protocol. O&P protocol employs monthly observation until relapse, then 2-week interval adjustments.[1]

*In the **treatment-naïve cohort (N=91)**, two adverse events were recorded (2.2%). These included one RPE tear (1.1%) and one case of IOI with vitritis (1.1%).*[1]

Please see the EYLEA 8 mg Summary of Product Characteristics for full details of the safety profile.

Patient demographics for treatment-naïve patients[1]

Eyes, N	91
Median age, years	80
Female, %	63

Treatment-naïve patients

Fast drying after the first dose with EYLEA 8 mg, sustained to Month 12[1]

Change in fluid in the central 1 mm zone over time



EYLEA 8 mg provided **early fluid control** after one injection, which was **sustained through Month 12**

Extended treatment intervals and sustained drying with EYLEA 8 mg[1]

Treatment interval at Month 12



Fluid-free patients at each treatment interval



Sustained drying with EYLEA 8 mg[1]

Mean (SD) CRT

Baseline	**375.0**	***P*<0.001**
N=91	(±163.7)	
Month 12	**265.2**	
N=91	(±73)	

Mean (SD) CST

Baseline	**390.6**	***P*<0.001**
N=91	(±142.4)	
Month 12	**277.3**	
N=91	(±72.8)	

Mean (SD) PED

Baseline	**226**	***P*<0.82**
N=91	(±181.2)	
Month 12	**139.9**	
N=91	(±79.9)	

From a baseline of 68.4 ETDRS letters, mean VA was **71.5 and 68.8 ETDRS letters** at **6 months and 12 months** of EYLEA 8 mg treatment, respectively[1]

Abbreviations:
CRT, central retinal thickness; **CST**, central subfield thickness; **ETDRS**, Early Treatment Diabetic Retinopathy Study; **IRF**, intraretinal fluid; **IVT**, intravitreal; **nAMD**, neovascular age-related macular degeneration; **O&P**, observe-and-plan; **PED**, pigment epithelial detachment; **qX**, every X weeks; **SD**, standard deviation; **SRF**, subretinal fluid; **T&E**, treat-and-extend; **VA**, visual acuity.

Reference:
1. Grimaldi G *et al*. Ophthalmol Ther 2026. DOI: 10.1007/s40123-025-01305-w. Online ahead of print.

May 2026 | PP-EYL_8mg-GB-1045

Prescribing information and adverse event reporting information for EYLEA® (aflibercept) is available via the QR code on the right.
Either click **here** or scan the QR code for prescribing information and adverse event reporting information.
For direct access to this prescribing information, please ensure your device's browser settings have automatic PDF download enabled.

This is a promotional poster produced and fully funded by Bayer plc for UK healthcare professionals only. Prescribing information and adverse event reporting information for EYLEA® (aflibercept) 2 mg and EYLEA 8 mg can be accessed via the link or QR code located at the bottom of this document.

EYLEA® 8mg
(aflibercept 114.3mg/mL, solution for injection)

Global EYLEA® (aflibercept) 8 mg real-world evidence

12-month real-world outcomes in patients from Switzerland with DMO

Swiss Retina Research Network (SRRN)

DMO

These data are from real patients. Individual results may vary.

Study design:
Retrospective study evaluated outcomes in 42 treatment-naïve eyes and 114 previously treated eyes with DMO. Eligible participants were adults (≥18 years old) with treatment-naïve or pre-treated DMO who received EYLEA 8 mg for 12 (±1) months.

Previously treated eyes were scheduled at the same interval as the last injection prior to switching. Patients were monitored after one injection, 3 months after switch, 6 months after switch, 12 months after switch and 18 months after switch to EYLEA 8 mg.

Previous treatment: 61.4% EYLEA 2 mg; 36.0% faricimab; 2.6% ranibizumab

Patient demographics

Eyes, N	
Treatment-naïve	42
Previously treated	114
Mean age, years	
Treatment-naïve	61.9
Previously treated	64.6
Female, %	
Treatment-naïve	29.0
Previously treated	34.4

Fast and sustained drying
with EYLEA 8 mg in previously treated patients

Fluid status over time
(N=114)



EYLEA 8 mg provided **early fluid control** after one injection, which was **sustained through Month 12** (N=114)

Extended treatment intervals
with EYLEA 8 mg in previously treated patients

Treatment intervals
(N=114)



More patients achieved extended intervals with EYLEA 8 mg vs. previous treatment (N=114)

Drying outcomes with EYLEA 8 mg

Change in CRT over time



–127.6 µm
Mean change in CRT with EYLEA 8 mg in **treatment-naïve patients** (N=42)

Vision outcomes with EYLEA 8 mg

Change in VA over time



+5.2 ETDRS letters
Mean change in VA with EYLEA 8 mg in **treatment-naïve patients** (N=42)

Ocular events were observed in previously treated patients only. Six adverse events were reported in the previously treated DMO cohort, including three cases of IOI, two cases of early IOP elevation and one case of vitreous haemorrhage. One patient death occurred due to systemic causes, with no other systemic adverse findings reported. All cases of IOI were successfully managed with topical therapy.

Please see the EYLEA 8 mg Summary of Product Characteristics for full details of the safety profile.

Abbreviations:
CRT, central retinal thickness; **DMO**, diabetic macular oedema; **ETDRS**, Early Treatment Diabetic Retinopathy Study; **IOI**, intraocular inflammation; **IOP**, intraocular pressure; **IRF**, intraretinal fluid; **qX**, every X weeks; **SRF**, subretinal fluid; **VA**, visual acuity.

Reference:
Spinder J *et al*. Ophthalmol Sci 2026; 6 (4): 101087. DOI: 10.1016/j.xops.2026.101087.

May 2026 | PP-EYL_8mg-GB-1045

Prescribing information and adverse event reporting information for EYLEA® (aflibercept) is available via the QR code on the right.
Either click **here** or scan the QR code for prescribing information and adverse event reporting information.
For direct access to this prescribing information, please ensure your device's browser settings have automatic PDF download enabled.